Suppr超能文献

英国和爱尔兰的肝移植前终末期肝病模型(MELD)评分与肝移植后生存率

Pretransplant MELD score and post liver transplantation survival in the UK and Ireland.

作者信息

Jacob Mathew, Copley Lynn P, Lewsey James D, Gimson Alex, Toogood Giles J, Rela Mohamed, van der Meulen Jan H P

机构信息

Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK.

出版信息

Liver Transpl. 2004 Jul;10(7):903-7. doi: 10.1002/lt.20169.

Abstract

It has been shown that the model for end-stage liver disease (MELD) score is an accurate predictor of survival in patients with liver disease without transplantation. Four recent studies carried out in the United States have demonstrated that the MELD score obtained immediately prior to transplantation is also associated with post-transplant patient survival. Our aim was to evaluate how accurately the MELD score predicts 90-day post-transplant survival in adult patients with chronic liver disease in the UK and Ireland. The UK and Ireland Liver Transplant Audit has data on all liver transplants since 1994. We studied survival of 3838 adult patients after first elective liver transplantation according to United Network for Organ Sharing categories of their MELD scores (< or = 10, 11-18, 19-24, 25-35, > or =36). The overall survival at 90-days was 90.2%. The 90-day survival varied according to the United Network for Organ Sharing MELD categories (92.6%, 91.9%, 89.7%, 89.7%, and 70.8%, respectively; P < 0.01). Therefore, only those patients with a MELD score of 36 or higher (3% of the patients) had a survival that was markedly lower than the rest. As a consequence, the ability of the MELD score to discriminate between patients who were dead or alive was poor (c-statistic 0.58). Re-estimating the coefficients in the MELD regression model, even allowing for nonlinear relationships, did not improve its discriminatory ability. In conclusion, in the UK and Ireland the MELD score is significantly associated with post-transplant survival, but its predictive ability is poor. These results are in agreement with results found in the United States. Therefore, the most appropriate system to support patient selection for transplantation will be one that combines a pretransplant survival model (e.g., MELD score) with a properly developed post-transplant survival model.

摘要

研究表明,终末期肝病模型(MELD)评分是未接受肝移植的肝病患者生存情况的准确预测指标。美国近期开展的四项研究表明,移植前即刻获得的MELD评分也与移植后患者的生存情况相关。我们的目的是评估MELD评分对英国和爱尔兰慢性肝病成年患者移植后90天生存情况的预测准确性。英国和爱尔兰肝脏移植审计机构拥有自1994年以来所有肝脏移植的数据。我们根据器官共享联合网络(United Network for Organ Sharing)对3838例首次择期肝移植成年患者的MELD评分分类(≤10、11 - 18、19 - 24、25 - 35、≥36)研究其生存情况。90天的总体生存率为90.2%。90天生存率根据器官共享联合网络的MELD分类有所不同(分别为92.6%、91.9%、89.7%、89.7%和70.8%;P < 0.01)。因此,只有MELD评分36分及以上的患者(占患者总数的3%)生存率明显低于其他患者。结果,MELD评分区分患者生死的能力较差(c统计量为0.58)。重新估计MELD回归模型中的系数,即使考虑非线性关系,也未能提高其区分能力。总之,在英国和爱尔兰,MELD评分与移植后生存情况显著相关,但其预测能力较差。这些结果与美国的研究结果一致。因此,支持患者移植选择的最合适系统将是一个将移植前生存模型(如MELD评分)与完善的移植后生存模型相结合的系统。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验